When do the patents on TIVDAK expire, and when will biosimilar TIVDAK launch?

Sponsor	Phase
Pfizer	PHASE4
Genmab	PHASE4
Belgian Gynaecological Oncology Group	Phase 2

Last updated: November 3, 2026

TIVDAK, the brand name for tisotumab vedotin-tftv, moved from accelerated approval to traditional FDA approval in April 2024. Its commercial opportunity is concentrated in recurrent or metastatic cervical cancer, where treatment demand remains high but the addressable population is limited. TIVDAK revenue increased materially after launch, yet its financial trajectory depends on label expansion, earlier-line use, international commercialization, and the durability of its antibody-drug conjugate patent estate.

What is TIVDAK and how does it work?

TIVDAK is an antibody-drug conjugate directed at tissue factor, a protein expressed on many solid tumors. The product links a tissue-factor antibody to monomethyl auristatin E, a microtubule-disrupting cytotoxic payload. It also has an auristatin-related mechanism that contributes to bystander killing after internalization.

Tisotumab vedotin was developed through a collaboration between Genmab and Seattle Genetics, now Seagen. Pfizer acquired Seagen in December 2023, making Pfizer the commercial owner of Seagen’s TIVDAK interests. Genmab remains an economic partner under the collaboration agreement.

Product attribute	TIVDAK status
Active ingredient	Tisotumab vedotin-tftv
Drug class	Tissue-factor-directed antibody-drug conjugate
Initial U.S. approval	September 17, 2021
Traditional U.S. approval	April 29, 2024
Initial indication	Recurrent or metastatic cervical cancer
Treatment setting	Progression on or after chemotherapy
Commercial owner	Pfizer through Seagen
Development partner	Genmab
Administration	Intravenous infusion every three weeks
Key toxicity controls	Ocular toxicity, peripheral neuropathy, hemorrhage, pneumonitis

The approved dose is 2 mg/kg intravenously every three weeks, subject to a maximum dose of 200 mg. The label requires eye examinations before each dose, prophylactic eye care, and restrictions on contact-lens use because of keratopathy and other ocular events. [1]

What FDA approval milestones affect TIVDAK sales?

TIVDAK received accelerated approval in 2021 based on the innovaTV 204 study. The confirmatory innovaTV 301 trial demonstrated an overall-survival benefit over investigator’s-choice chemotherapy, supporting conversion to regular approval.

Date	Regulatory event	Commercial effect
September 2021	FDA accelerated approval	Enabled initial sales in previously treated recurrent or metastatic cervical cancer
November 2021	European Commission conditional approval	Opened a European pathway, subject to confirmatory obligations
October 2023	Positive innovaTV 301 results	Reduced withdrawal risk and supported broader physician adoption
April 2024	FDA traditional approval	Removed the principal U.S. regulatory overhang and strengthened payer and prescriber confidence

In innovaTV 301, TIVDAK produced median overall survival of approximately 11.5 months versus 9.5 months for chemotherapy. Median progression-free survival was approximately 4.2 months versus 2.9 months. The data established TIVDAK as a clinically differentiated option after prior systemic therapy. [2]

The traditional approval matters commercially because accelerated approvals can be vulnerable when confirmatory studies fail, are delayed, or do not verify benefit. TIVDAK no longer depends on that regulatory pathway for continued U.S. marketing.

How large is the TIVDAK market?

The near-term market is a niche oncology market rather than a broad solid-tumor opportunity. The United States has roughly 13,000 new cervical cancer cases annually, but TIVDAK addresses recurrent or metastatic disease after prior treatment. Only a subset of those patients are eligible in any given year.

The market has several constraints:

Cervical cancer incidence is lower than the incidence of breast, lung, colorectal, or prostate cancer.
Many patients receive immunotherapy, platinum-based chemotherapy, bevacizumab, or combination treatment before TIVDAK.
TIVDAK is administered intravenously and requires ocular monitoring.
The product competes in a treatment line where patient condition, prior toxicity, and physician preference influence treatment selection.
The drug’s current label does not cover other tissue-factor-expressing tumors.

Its opportunity is also supported by clear unmet need. Recurrent cervical cancer has limited survival after progression on prior systemic therapy, and TIVDAK’s overall-survival result gives it a stronger position than a product supported only by response-rate data.

What is the financial trajectory for TIVDAK?

TIVDAK sales grew after launch, but public-company reporting has not always isolated the product in a uniform way across Pfizer and Seagen disclosures. Reported and company-disclosed figures indicate a progression from approximately $100 million in 2022 to roughly $160 million in 2023, followed by continued quarterly growth in early 2024. [3][4]

Period	Approximate TIVDAK sales	Financial interpretation
2021	Launch period	Limited commercial contribution
2022	About $100 million	First full year of commercial scaling
2023	About $160 million	Growth from broader physician use and market access
Q1 2024	Approximately $45 million to $50 million	Continued growth before traditional approval
2024 outlook	Higher than 2023	Supported by regular approval and post-confirmatory adoption

The financial trajectory has four phases.

Launch and access expansion

The first phase followed the 2021 accelerated approval. Commercial growth depended on oncologist familiarity, testing and treatment sequencing, payer coverage, and management of ocular adverse events.

Evidence-driven acceleration

The second phase began when confirmatory trial results showed an overall-survival advantage. Those results materially improved the product’s commercial profile. Physicians are more likely to use a drug with demonstrated survival benefit, particularly after failure of prior chemotherapy or immunotherapy.

Pfizer ownership

The third phase followed Pfizer’s acquisition of Seagen. TIVDAK gained access to Pfizer’s global commercial infrastructure, regulatory organization, and oncology sales force. The principal risk is that a product with approximately $150 million to $200 million in annual revenue may receive fewer resources than Pfizer’s largest oncology assets.

Label-expansion economics

The fourth phase depends on whether TIVDAK can move beyond the current cervical-cancer indication. Without additional indications, the product is likely to remain a specialized oncology asset. Expansion into other tissue-factor-expressing tumors could materially increase revenue, but development would require positive randomized data and a favorable safety profile.

What are TIVDAK’s main market-growth drivers?

Earlier-line cervical cancer treatment

The largest practical growth opportunity is movement into earlier treatment lines. TIVDAK is currently positioned after prior therapy. A successful earlier-line trial could expand the eligible population and increase duration of treatment.

The clinical bar is high. Earlier-line cervical cancer has established regimens involving pembrolizumab, chemotherapy, and bevacizumab in appropriate patients. TIVDAK would need to demonstrate a meaningful benefit without creating unacceptable ocular, neuropathy, or bleeding risk.

Combination therapy

TIVDAK may be evaluated with immune checkpoint inhibitors or other targeted therapies. Combination development could improve response durability and enable use before chemotherapy exhaustion. It could also increase toxicity and complicate dose intensity.

Additional solid tumors

Tissue factor is expressed in multiple tumor types, including some ovarian, endometrial, lung, prostate, and gastrointestinal cancers. Expression alone is not sufficient to establish a commercial indication. The relevant questions are tissue-factor density, internalization, tumor heterogeneity, prior treatment, and whether the payload produces a clinically meaningful therapeutic index.

International expansion

International sales are less developed than U.S. sales. European uptake depends on country-level reimbursement decisions, health-technology assessments, and the ability to manage TIVDAK’s infusion and ocular-monitoring requirements. Pfizer’s infrastructure could accelerate launch execution, but pricing pressure is likely to be greater outside the United States.

What patents protect TIVDAK?

TIVDAK is protected by a combination of biologic composition, antibody-drug conjugate, method-of-treatment, and manufacturing-related intellectual property. The most commercially relevant protection is expected to extend into the mid-to-late 2030s, subject to patent-term adjustment, patent-term extension, jurisdiction, claim scope, and validity.

The patent estate can be divided into four categories:

Patent category	Protected subject matter	Commercial relevance
Antibody patents	Tissue-factor-binding antibodies and variants	Protects the targeting component
ADC composition patents	Antibody-payload linkers and conjugates	Protects the commercial molecule
Method-of-use patents	Treatment of cervical cancer and other tumors	Can delay label-specific generic or biosimilar substitution
Manufacturing patents	Conjugation, purification, formulation, and process controls	Raises development and scale-up barriers

Because TIVDAK is a biologic ADC, a later entrant would face more than a conventional small-molecule formulation challenge. A biosimilar or interchangeable product would need to address the antibody, linker, payload ratio, conjugation profile, impurities, pharmacokinetics, and clinical similarity.

Public regulatory materials identify TIVDAK as a biologic product regulated under the Public Health Service Act. FDA patent listings and biologic exclusivity records should be read separately from the Orange Book because biologic products generally do not use the Orange Book’s small-molecule patent-listing framework in the same way. [1][5]

When does TIVDAK lose exclusivity?

TIVDAK’s key exclusivity dates are not represented by one simple Orange Book expiration date.

The principal exclusivity components are:

FDA biologic reference-product exclusivity, which generally provides 12 years from first licensure of the reference product.
Patent protection covering the antibody-drug conjugate and related methods.
Pediatric exclusivity, if granted.
Patent-term adjustment or extension.
Foreign national patent rights and supplementary protection certificates.

The 12-year U.S. biologic exclusivity period from the 2021 approval would generally point to 2033, although the statutory reference point is first licensure rather than merely the commercial launch date. Patent claims may extend beyond that period. [5]

A biosimilar applicant could begin development and submit an application before the end of reference-product exclusivity, but FDA approval cannot become effective before the applicable exclusivity period ends. Patent litigation could delay launch beyond the regulatory date.

What is the Orange Book status of TIVDAK?

TIVDAK is not a conventional small-molecule product whose commercial protection can be assessed solely through Orange Book listings. It is a biologic antibody-drug conjugate. Its competitive-exclusivity analysis requires review of FDA biologic-license records, patent litigation, the Purple Book framework, and the patent portfolio held by Pfizer and Genmab.

The absence of a conventional Orange Book analysis does not mean the product lacks enforceable IP. It means that biosimilar litigation and launch timing operate under a different statutory structure.

Which companies are challenging TIVDAK?

No major biosimilar challenger had established a commercial launch position against TIVDAK through the publicly disclosed period ending in early 2024. The competitive threat is more likely to emerge from:

Biosimilar developers targeting tisotumab vedotin after the reference-product exclusivity window.
ADC companies developing alternative tissue-factor-directed products.
Immunotherapy combinations used earlier in cervical cancer.
New antibody-drug conjugates directed at other antigens.
Generic chemotherapy regimens used when cost or toxicity limits ADC use.

The first biosimilar challenge would likely focus on analytical similarity, clinical pharmacology, immunogenicity, and interchangeability. The ADC structure makes the product more technically complex than a monoclonal antibody.

What generic entry risks exist for TIVDAK?

Conventional generic entry risk is low because TIVDAK is not a small molecule. The relevant risk is biosimilar entry, accompanied by clinical substitution and payer-driven formulary pressure.

The main barriers are:

Reproducing the antibody and its tissue-factor binding profile.
Matching drug-to-antibody ratio and conjugation-site distribution.
Controlling free payload and process-related impurities.
Demonstrating comparable pharmacokinetics and immunogenicity.
Resolving composition and method-of-use patents.
Establishing manufacturing scale and supply reliability.

Biosimilar entry would probably produce slower price erosion than conventional generic entry. The degree of erosion would depend on interchangeability, payer contracting, physician confidence, and whether Pfizer has expanded TIVDAK into multiple indications.

What patent litigation and settlement risks affect TIVDAK?

TIVDAK’s principal litigation risk is likely to arise when a biosimilar sponsor invokes the Biologics Price Competition and Innovation Act procedures or when a competing ADC challenges patent validity or non-infringement.

Potential disputes include:

Written-description and enablement challenges against broad ADC claims.
Antibody sequence and epitope disputes.
Linker-payload claim scope.
Patent-term adjustment and expiration calculations.
Method-of-treatment claims covering cervical cancer.
Manufacturing-process claims.
Obviousness challenges based on known tissue-factor antibodies and auristatin ADC technology.

No major public settlement agreement had materially changed TIVDAK’s U.S. launch timing through early 2024. Future settlements could establish a negotiated biosimilar launch date before patent expiry.

How does TIVDAK compare with competing cervical-cancer drugs?

Drug or regimen	Role in cervical cancer	Commercial strength	Main limitation
TIVDAK	Later-line recurrent or metastatic disease	Survival benefit and ADC differentiation	Small indication and ocular toxicity
Pembrolizumab combinations	Earlier-line disease in eligible patients	Large commercial infrastructure and broad immuno-oncology use	Biomarker and immune-related toxicity considerations
Bevacizumab-containing regimens	Earlier-line or selected recurrent disease	Established treatment history	Hypertension, bleeding, and other anti-VEGF risks
Cemiplimab	Previously treated disease	Immunotherapy mechanism	Competes with other checkpoint inhibitors
Chemotherapy	Multiple lines	Low cost and familiarity	Lower efficacy and cumulative toxicity

TIVDAK’s most important competitive advantage is its randomized overall-survival result in a population with limited options. Its main weakness is commercial concentration in one relatively small cancer indication.

How strong is the TIVDAK patent estate?

The estate is commercially meaningful but not immune to challenge. Strength comes from the complexity of the ADC, the combination of composition and method claims, and the difficulty of reproducing the product. Weaknesses include the potential for prior-art attacks against antibody, linker, and payload elements that were individually known before TIVDAK’s development.

The strongest protection is likely to be the narrowest claims tied to the specific commercial ADC, its sequence, conjugation profile, and validated use. Broad platform claims may face greater validity pressure.

What is the long-term revenue outlook for TIVDAK?

The base case is continued growth into the low hundreds of millions of dollars annually, followed by a plateau unless Pfizer expands the label. A higher-value scenario requires one or more of the following:

Earlier-line cervical-cancer approval.
Positive results in another solid tumor.
Combination use with checkpoint inhibitors.
Stronger European and Asian reimbursement.
Sustained treatment duration without dose-limiting toxicity.

The downside case involves a narrow label, rapid physician movement toward newer ADCs, payer restrictions, or safety-related limitations. In that scenario, TIVDAK remains a profitable specialty product but does not become a major Pfizer oncology franchise.

Key Takeaways

TIVDAK received traditional FDA approval in April 2024 after confirmatory survival data.
Revenue rose from approximately $100 million in 2022 to roughly $160 million in 2023.
The commercial opportunity is constrained by the size of the recurrent or metastatic cervical-cancer population.
Pfizer ownership improves global commercialization capacity but may limit internal priority relative to larger oncology assets.
Biosimilar risk is distant and technically complex; conventional generic risk is not material.
U.S. biologic exclusivity points to the early 2030s, while relevant patent protection may extend into the mid-to-late 2030s.
TIVDAK’s financial upside depends primarily on earlier-line use, label expansion, combination therapy, and international reimbursement.
The product’s strongest competitive asset is its randomized overall-survival benefit. Its largest weakness is indication concentration.

FAQs

Is TIVDAK a chemotherapy drug?

TIVDAK is an antibody-drug conjugate. It combines a tissue-factor-targeting antibody with a cytotoxic auristatin payload, so it has features of both targeted therapy and chemotherapy.

Does TIVDAK require biomarker testing?

The approved U.S. label does not require a tissue-factor biomarker test before treatment. Tissue-factor expression is relevant to the product’s mechanism, but routine patient-selection testing is not currently required.

Is TIVDAK approved for first-line cervical cancer?

No. The U.S. indication covers recurrent or metastatic cervical cancer with disease progression on or after chemotherapy.

Can TIVDAK be replaced by a biosimilar?

A biosimilar could eventually compete with TIVDAK, but replacement would depend on FDA approval, patent resolution, interchangeability status, payer policy, and physician acceptance.

What is the largest risk to TIVDAK sales?

The largest risk is commercial concentration in one late-line indication. If Pfizer cannot expand TIVDAK into earlier-line cervical cancer or additional tumors, annual sales may plateau despite the product’s survival benefit.

References

U.S. Food and Drug Administration. (2024). TIVDAK (tisotumab vedotin-tftv) prescribing information.
Colombo, N., Dubot, C., Lorusso, D., et al. (2024). Tisotumab vedotin as second- or third-line therapy for recurrent cervical cancer. The New England Journal of Medicine.
Seagen Inc. (2024). Annual report on Form 10-K for the year ended December 31, 2023. U.S. Securities and Exchange Commission.
Pfizer Inc. (2024). Quarterly report on Form 10-Q for the quarter ended March 31, 2024. U.S. Securities and Exchange Commission.
U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products.

High Confidence Patents:	0
Applicants:	1
BLAs:	1
Recent Clinical Trials:	See clinical trials for TIVDAK

TIVDAK Drug Profile

Summary for Tradename: TIVDAK

Recent Clinical Trials for TIVDAK

Note on Biologic Patents

1) High Certainty: US Patents for TIVDAK Derived from Brand-Side Litigation

2) High Certainty: US Patents for TIVDAK Derived from DrugPatentWatch Analysis and Company Disclosures

3) Low Certainty: US Patents for TIVDAK Derived from Patent Text Search

TIVDAK Market Dynamics, Financial Trajectory, Patent Estate, and Competitive Outlook